Pia Kvistborg, ESMO 2020 – The ORF1ab of SARS-CoV-2 Encodes an Immunodominant Epitope Restricted by HLA-A*01:01
Access all of the content
touchIMMUNOLOGY meets Dr Pia Kvistborg at the Virtual 2020 ESMO Congress to discuss the presentation of her late-breaking abstract ‘The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01’ (LBA73) and initial findings from her recent study.
- How did your collaboration with Andrea Cossarizza on SARS-CoV-2 come about? (0:12)
- How have you applied cancer research technology to elucidate structural components of the SARS-CoV-2 virus? (1:04)
- Could you give us an overview of the aims and design of your recent study? (2:40)
- What were the main findings of your study? (4:48)
- What are the implications of these findings on vaccine design? (10:55)
Speaker Disclosure: Pia Kvistborg has nothing to disclose in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In COVID-19
Alessio Cortellini, ESMO Immuno-Oncology 2022: Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer
A joint analysis of patients receiving immune checkpoint inhibitor therapy was conducted using the OnCovid (NCT04393974) and ESMO CoCARE registries, this assessed SARS-CoV-2 outcomes in vaccinated and unvaccinated patients with cancer and whether prior immune-related adverse events affected these outcomes. In this touchIMMUNOLOGY interview, we spoke with Dr Alessio Cortellini (Fondazione Policlinico Universitario Campus Bio-Medico, […]
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Giovanni Marasco, UEG Week 2022: Findings from the GI-COVID-19 Study
The GI-COVID-19 study (ClinicalTrials.gov NCT04691895) was a prospective, multicenter, controlled study investigating the prevalence of gastrointestinal (GI) symptoms in hospitalized patients with COVID-19. We were delighted to talk with Dr. Giovanni Marasco (Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy) to discuss the aims, methodology and findings in terms of prevalence of GI symptoms in patients with COVID-19 […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!